Tamoxifen: An enduring star

Journal of the National Cancer Institute

Volumn 99, Issue 4, 2007, Pages 258-260

  Veronesi, Umberto ^a   Maisonneuve, Patrick ^a   Decensi, Andrea ^a,b  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b GALLIERA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; ESTROGEN RECEPTOR; PLACEBO; RALOXIFENE; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

BREAST CANCER; BREAST CARCINOGENESIS; CANCER INVASION; CANCER RISK; CARCINOMA IN SITU; CARDIOVASCULAR DISEASE; CATARACT; CLINICAL TRIAL; COLORECTAL ADENOMA; COST BENEFIT ANALYSIS; COST CONTROL; DEEP VEIN THROMBOSIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; ESTROGEN ACTIVITY; FRACTURE; GYNECOLOGIC DISEASE; HEART INFARCTION; HIGH RISK PATIENT; HORMONE SUBSTITUTION; HUMAN; LOW DRUG DOSE; LUNG EMBOLISM; OVERALL SURVIVAL; PREMENOPAUSE; PRIORITY JOURNAL; RETINA BLOOD VESSEL OCCLUSION; RISK BENEFIT ANALYSIS; RISK REDUCTION; SEX DIFFERENCE; TREATMENT RESPONSE; VASOMOTOR DISORDER; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; CHEMISTRY; CONTROLLED CLINICAL TRIAL; FEMALE; FOLLOW UP; INCIDENCE; MULTICENTER STUDY; NOTE; RANDOMIZED CONTROLLED TRIAL; RISK; RISK ASSESSMENT; RISK FACTOR; TIME; VEIN THROMBOSIS;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; ESTROGEN RECEPTOR MODULATORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MULTICENTER STUDIES; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ESTROGEN; RISK ASSESSMENT; RISK FACTORS; TAMOXIFEN; TIME FACTORS; VENOUS THROMBOSIS;

EID: 33847785696     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djk072     Document Type: Editorial

References (23)

1. Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli Y, Howell A, for the International Breast Cancer Intervention Study (IBIS) I Investigators. Long-term results of tamoxifen prophylaids for breast cancer - 96 month follow-up of the randomized IBIS-I study. J Natl Cancer Inst 2007;99:272-82.
2. Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 2007;99:283-90.
3. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, et al. Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005;97:1652-62.
4. Early Breast Cancer Trialists' Collaborative Group [EBCTCG]. Effects of chemotherapy and hormonal therapy for early breast cancer on recurence and 15-year survival: An overview of the randomised trials. Lancet 2005;365:1687-717.
5. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al.; National Surgical Adjuvant Breast and Bowel Project [NSABP]. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene [STAR] P-2 trial [erratum in JAMA 2006; 296:2926]. JAMA 2006;295:2727-41.
6. Decensi A, Galli A, Veronesi U. HRT opposed to low-dose tamoxifen [HOT study]: Rationale and design. Recent results. Cancer Res 2003;163: 104-11; discussion 264-6.
7. Coombes RC, Paridaens R, Jassem J, Van de Velde CJ, Delozier T, Jones SE, et al. First mature analysis of the Intergroup Exemestane Study. J Clin Oncol 2006;24:LBA 527.
8. Costantino JP, Gail MH, Pee D, Anderson S, Redmond CK, Benichou J, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 1999;91:1541-8.
9. Huang WY, Newman B, Millikan RC, Schell MJ, Hulka BS, Moorman PG. Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. Am J Epidemiol 2000; 151:703-14.
10. Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE. Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst 2004;96:218-28.
11. Rosenberg LU, Einarsdottir Y, Friman EI, Wedren S, Dickman PW, Hall P, et al. Risk factors for hormone receptor-defined breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2006;15: 2482-8.
12. Suzuki R, Ye W, Rylander-Rudqvist T, Saji S, Colditz GA, Wolk A. Alcohol and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status: A prospective cohort study. J Natl Cancer Inst 2005;97:1601-8.
13. Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst 2004;96: 1856-65.
14. Veronesi U, Maisonneuve P, Rotmensz N, Costa A, Sacchini V, Travaglini R, et al. Italian Tamoxifen Study Group. Italian randomized trial among women with hysterectomy: Tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst 2003;95:160-5.
15. Decensi A, Maisonneuve P, Rotmensz N, Bettega D, Costa A, Sacchini V, et al. Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation 2005;111:650-6.
16. Bruno S, Maisonneuve P, Castellana P, Rotmensz N, Rossi S, Maggioni M, et al. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ 2005;330:932-5.
17. Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A, et al.; IBIS investigators. First results from the International Breast Cancer Intervention Study (IBIS-I): A randomised prevention trial. Lancet 2002; 360:817-24.
18. Decensi A, Bonanni B, Guerrieri-Gonzaga A, Gandini S, Robertson C, Johansson H, et al. Biologic activity of tamoxifen at low doses in healthy women. J Natl Cancer Inst 1998;90:1461-7.
19. Guerrieri-Gonzaga A, Baglietto L, Johansson H, Bonanni B, Robertson C, Sandri MT, et al. Correlation between tamoxifen elimination and biomarker recovery in a primary prevention trial. Cancer Epidemiol Biomarkers Prev 2001;10:967-70.
20. Decensi A, Robertson C, Viale G, Pigatto F, Johansson H, Kisanga ER, et al. A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst 2003;95:779-90.
21. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998;90:1371-88.
22. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al.; Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80.
23. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al.; Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial [erratum in N Engl J Med 2006;355:221]. N Engl J Med 2005;352:1092-102.